- JTC-801
-
- $41.00
-
2026-04-21
- CAS:244218-51-7
- Purity: 99.59%
- Supply Ability: 10g
- JTC 801
-
- $9.80
-
2020-01-13
- CAS:244218-51-7
- Min. Order: 1g
- Purity: ≥99%
- Supply Ability: 100kg
|
| | JTC 801 Basic information |
| Product Name: | JTC 801 | | Synonyms: | JTC 801;N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamidehydrochloride;N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamide monohydrochloride;JTC 801 HCl;JTC-801 hydrochloride;JTC-801/JTC801;N-(4-AMino-2-Methyl-quinolin-6-yl)-2-(4-ethyl-phenoxyMethyl)-benzaMide hydrochloride;Benzamide,N-(4-amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]-, hydrochloride | | CAS: | 244218-51-7 | | MF: | C26H25N3O2.ClH | | MW: | 447.963 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 244218-51-7.mol |  |
| | JTC 801 Chemical Properties |
| Melting point | 235℃ | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMSO: ≥20mg/mL | | form | powder | | color | tan | | InChI | 1S/C26H25N3O2.ClH/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25;/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30);1H | | InChIKey | NQLIYKXNAXKMBL-UHFFFAOYSA-N | | SMILES | C(=O)(C1C=CC=CC=1COC1C=CC(CC)=CC=1)NC1C=CC2=NC(C)=CC(N)=C2C=1.Cl |
| Hazard Codes | Xi | | Risk Statements | 36 | | Safety Statements | 26 | | WGK Germany | 1 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2 |
| | JTC 801 Usage And Synthesis |
| Uses | JTC 801 is a novel opioid receptor-like1 (ORL1) receptor antagonist. | | Biological Activity | High affinity, selective NOP receptor antagonist (K i = 8.2 nM). Displays approximately 12.5-, 129- and 1055-fold selectivity over human μ -, κ - and δ -opioid receptors respectively. In vivo shows anti-nociceptive effects in acute pain models. Orally active. | | in vivo | JTC-801 (≥0.01mg/kg, i.v. or 1mg/kg, p.o.) antagonizes the nociceptin-induced allodynia in mice. In mouse hot-plate test, JTC-801 prolongs escape response latency (ERL) to exposed heat stimulus with minimum effective doses (MED) of 0.01mg/kg by i.v. or 1mg/kg by p.o. In the rat formalin test, JTC-801 reduces both the first and second phases of the nociceptive response with MED of 0.01mg/kg by i.v. administration or 1mg/kg by p.o. administration. This anti-nociceptive action of JTC-801 is not inhibited by naloxone (10mg/kg, s.c.). JTC-801 antagonizes the ORL1 receptor response, and has efficacious and potent anti-nociceptive effects in acute pain animal models not only by intravenous injection but also oral administration[1]. JTC-801 (0.3 mg/kg) decreases allodynia induced by the intrathecal injection of nociceptin in mice[2]. JTC-801 (6 mg/kg i.p., once daily) reverses SPS-induced mechanical allodynia, thermal hyperalgesia, anxiety-like behaviour and hypocortisolism. JTC-801 treatment also reverses NOP receptor protein and mRNA up-regulation in amygdala and PAG. JTC-801 blocks elevated N/OFQ levels in serum, CSF, PAG and hippocampus at day 21 of SPS[3]. JTC-801 (0.05-5 mg/kg, i.p.) supresses the the analgesic effect of N2O in 129Sv mice by the writhing test and tail flick test[4]. | | IC 50 | NOP Receptor/ORL1 | | storage | Desiccate at RT |
| | JTC 801 Preparation Products And Raw materials |
|